Here's Why You Should Add PacBio Stock to Your Portfolio Now
PacBio (PACB) is positioned for growth due to its innovative sequencing technologies, strong product portfolio, and solid first-quarter results. The company's HiFi long-read sequencing and Onso short-read platform are driving market leadership, despite facing headwinds from funding uncertainties in academic and government research. Analysts expect continued strong performance and have maintained a stable estimate revision trend for 2026.
Pacific Biosciences updates its sequencing strategy. Investors watch long-read technology
Pacific Biosciences is refining its strategy in the genomic sequencing market by focusing on high-accuracy long-read technologies, which are gaining importance across research and clinical applications. The company generates revenue by selling instruments, consumables, and services, primarily to research institutions. This strategic emphasis positions Pacific Biosciences in a crucial area where comprehensive genomic information is increasingly vital for understanding genetic diversity, rare variants, and full genome architecture.
Earnings call transcript: Pacific Biosciences reports Q1 2026 earnings beat
Pacific Biosciences (PACB) reported a mixed Q1 2026, beating EPS expectations with -$0.12 against a forecasted -$0.14, but missing revenue targets at $37.2 million compared to an anticipated $39.98 million. Despite flat year-over-year revenue, consumables grew by 9%, offsetting a 12% decline in instrument revenue. The company's stock saw a modest 0.47% aftermarket increase as it lowered its full-year revenue guidance to $165-$175 million due to softer-than-expected instrument demand and increasing computing component costs, though it remains optimistic about clinical adoption and upcoming product launches like SparkNext chemistry.
Pacific Biosciences Q1 2026 slides: consumables hit record amid product launch
Pacific Biosciences (NASDAQ:PACB) reported a mixed Q1 2026, beating earnings expectations but missing on revenue. The company saw record consumables revenue, driven by clinical adoption, while instrument sales declined. A significant upcoming product launch, SPRQ-Nx, is expected to improve HiFi sequencing economics and the company's margin profile, alongside major collaborations aimed at expanding genetic diversity research and clinical genomics.
Is Pacific Biosciences (PACB) The Best Rising Penny Stock?
Pacific Biosciences of California, Inc. (PACB) has seen significant gains recently, rising over 12% in the past month and 35% since the launch of SPRQ-Nx sequencing chemistry. Wall Street analysts predict a 59% upside. The company's new chemistry reduces genome sequencing costs and introduces a reusable consumable, alongside an upgraded AI-powered accuracy tool developed with Google.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) stock dropped 2.89% to $1.68, underperforming major market indices on a day led by gains. Despite this, the company's shares have risen 9.49% over the past month, surpassing its sector and the S&P 500. Investors are now awaiting its financial report, with expectations of a 7.69% decrease in EPS but a 5.86% rise in revenue compared to the prior-year quarter.
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell Small Cap Comp Growth Benchmark
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) has been added to the Russell Small Cap Comp Growth Benchmark. This addition highlights the company's position as a life science technology firm specializing in designing and manufacturing sequencing solutions, including its HiFi long-read sequencing technology. The company's products cater to various applications such as human germline sequencing, plant and animal sciences, infectious disease, microbiology, and oncology research.
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000 Growth Benchmark
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) has been added to the Russell 3000 Growth Benchmark. This news, published on June 28, 2026, marks the company's inclusion in several Russell growth indices, including the Russell Small Cap Comp Growth, Russell 2500 Growth, and Russell 2000 Growth Benchmarks. The company, which specializes in life science technology and sequencing solutions, recently announced earnings results, provided guidance for 2026, and reported collaborations and changes to its board of directors.
Pacific Biosciences of California, Inc.(NasdaqGS:PACB) added to Russell 3000E Growth Benchmark
Pacific Biosciences of California, Inc. (NasdaqGS:PACB) has been added to the Russell 3000E Growth Benchmark. The company, a life sciences technology firm, specializes in designing and manufacturing sequencing solutions, primarily known for its HiFi long-read sequencing technology. This inclusion highlights its growth trajectory and recognition in the market.
Enterprise value to EBITDA forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB
This article provides financial information for Pacific Biosciences of California, Inc. (NASDAQ: PACB), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock is listed on the Nasdaq Stock Market and that the market was closed at the time the data was accessed. The content is presented through TradingView, a platform providing market data and financial tools.
Price to sales forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB
This article provides access to the "Price to sales forward" financial data for Pacific Biosciences of California, Inc. (NASDAQ: PACB) on the TradingView platform. It highlights that this specific financial metric is unavailable at the moment, indicating either no current data entry or it's a field that hasn't been populated yet. The article serves as a placeholder for financial information regarding the company's valuation.
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions
Analysts have issued mixed changes to their price targets for Pacific Biosciences of California (PACB), with some increasing targets by $0.50 and others trimming them. These adjustments reflect differing views on the company's valuation and ability to meet expectations. While the fair value remains at $2.46 per share, key assumptions for revenue growth, profit margin, future P/E, and discount rate have seen minor changes.
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions
Analysts are making incremental adjustments to PacBio's (PACB) price targets, reflecting both growing comfort with the company's execution and ongoing concerns about meeting expectations. Barclays, for instance, has shifted its valuation framework multiple times, with small changes indicating a balanced risk-reward profile for the stock. Despite these target changes, PacBio's fair value remains stable at US$2.46 per share, with consistent revenue growth and profit margin assumptions.
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – NASDAQ:PACB
This article provides a financial data point for Pacific Biosciences of California, Inc. (NASDAQ: PACB), specifically its enterprise value to EBIT forward. The content appears to be a stub or a data point from a financial platform like TradingView, indicating no further details are available beyond the metric itself.
Pacific Biosciences of California, Inc. Actuals & Estimates (NASDAQ:PACB)
This article provides an overview of Pacific Biosciences of California, Inc. (NASDAQ: PACB), including its current stock price, historical performance, analyst forecasts, and key financial metrics. It highlights recent stock price movements, earnings results, revenue figures, market capitalization, and employee count, while also addressing frequently asked questions about the company's stock.
Enterprise value to revenue forward of Pacific Biosciences of California, Inc. – FWB:P09
This article displays the "Enterprise value to revenue forward" metric for Pacific Biosciences of California, Inc. (FWB:P09) on the TradingView platform. It provides financial data for the company sourced from ICE Data Services and FactSet for the Frankfurt Stock Exchange. The content primarily focuses on the display of this specific financial ratio for the company.
Enterprise value to EBIT forward of Pacific Biosciences of California, Inc. – FWB:P09
This article focuses on the enterprise value to EBIT forward metric for Pacific Biosciences of California, Inc. (FWB:P09) as displayed on the TradingView platform. It provides a snapshot of the company's financial data on the Frankfurt Stock Exchange within the Health Technology sector. The content primarily highlights the availability of this specific financial ratio for investors.
PACB Stock Gains Focus As New Sequencing Tech Slashes Genome Costs
Pacific Biosciences of California Inc. (PACB) stock has rallied due to its new SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio HiFi platform, drastically cutting the cost of human genome sequencing to about $345. This innovation, coupled with improved data quality, positions PACB to compete in population-scale and clinical genomics, attracting significant trader attention despite the company's current unprofitability and high leverage. The market is closely watching for confirmation that these technological advancements will translate into increased throughput and recurring revenue, making PACB a speculative, headline-driven trade.
PACB Forecast — Price Target — Prediction for 2027
This article provides a forecast for Pacific Biosciences of California, Inc. (PACB) stock, including analyst price targets and predictions for 2027. It details the current stock price, historical performance, market capitalization, and upcoming earnings report. The piece also includes frequently asked questions about the company's financials, employee count, and investment insights derived from technical analysis.
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides details on the dividend and stock split history for Pacific Biosciences of California Inc (PACB). It notes that PACB has distributed $0.00 in dividends over the past five years and reports no historical stock split data. The page also presents current stock performance details like market cap and recent price changes.
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Pacific Biosciences of California Inc (PACB), listing major shareholders and their respective proportions, as well as institutional holdings. It provides data on shareholder types, institutional shareholding trends over several quarters, and recent shareholder activity from key institutional investors. The report also includes a list of related ETFs that hold PACB shares.
Pacific Biosciences of California Inc (PACB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a detailed revenue breakdown for Pacific Biosciences of California Inc (PACB) for FY2024, categorizing revenue by business segment and geographical region. Consumable revenue forms the largest segment, followed by instrument revenue and service/other income. North America is the largest regional contributor, followed by Europe (including the Middle East and Africa) and Asia Pacific.
Pacific Biosciences of California Inc (PACB) Earnings Forecast: Future EPS & Revenue Growth Estimates
Pacific Biosciences of California Inc (PACB) has an earnings forecast score of 7.25, ranking 150 out of 203 in its industry, with analysts setting an average target price of $2.50. Based on 8 analyst ratings, the consensus for PACB stock is a "Buy." The company's expected revenue for the next quarter is $40.74 million, and its EPS for the previous quarter was -$0.13, with an expectation of -$0.13 for the upcoming quarter.
Pacific Biosciences of California Inc (PACB) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Pacific Biosciences of California Inc (PACB), highlighting its current valuation score of 7.76, ranking 131 out of 203 in the Healthcare Equipment & Supplies industry. It details the current P/E ratio of -3.27, noting its position relative to recent highs and lows. The report also mentions that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Pacific Biosciences of California Inc (PACB) Institutional Confidence
Pacific Biosciences of California Inc (PACB) has an institutional shareholding score of 5.00, placing it 109th out of 203 in the Healthcare Equipment & Supplies industry. Institutional investors hold 62.12% of shares, an increase of 10.93% quarter-over-quarter. Catherine Wood is the largest institutional shareholder with 37.12 million shares, representing 11.68% of outstanding shares.
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street?
Pacific Biosciences of California, Inc. (PACB) is highlighted as one of the top genomics stocks, with recent advancements in its SPRQ-Nx sequencing chemistry and Revio platform. The company has reduced per-genome sequencing costs and enhanced accuracy using AI-powered DeepConsensus. Despite its potential, the article suggests that some AI stocks may offer higher returns in a shorter timeframe.
5 Best Genomics Stocks to Buy According to Analysts
Pacific Biosciences of California, Inc. (NASDAQ:PACB) recently started global shipments of its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio platform, reducing per-genome costs to $345, with sub-$300 possible at scale. This new chemistry cuts costs by about 30% and improves accuracy and yield through updates to its AI-powered DeepConsensus algorithm developed with Google. Beta testing showed higher yield and lower failure rates, leading analysts to project a 63.79% upside potential for the company.
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) stock closed down 2.96% at $1.31, underperforming the broader market which saw gains across the S&P 500, Dow, and Nasdaq. Despite recent monthly gains in shares and its sector, the company faces an anticipated 7.69% decline in EPS for its upcoming earnings release. However, analysts have revised estimates upwards, leading to a Zacks Rank of #2 (Buy) for PACB.
Pacific Biosciences of California Company Profile & Introduction
This document provides a company profile and introduction for Pacific Biosciences of California.
Pacific Biosciences (PACB) director receives 223,492 stock options at $1.58 strike
Pacific Biosciences of California director Marshall Mohr was granted 223,492 stock options at an exercise price of $1.58 per share. These equity compensation options vest monthly over one year, contingent on his continued service as a director, and expire on June 3, 2036. This transaction is a routine grant and does not involve open-market trading, providing limited insight into the director's current view of the stock.
PACB (PACB) director granted 223,492 stock options at $1.58 exercise price
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) director Randall S. Livingston was granted 223,492 stock options at an exercise price of $1.58 per share. The options vest monthly over one year or earlier upon the next annual stockholder meeting, expiring on June 3, 2036. This grant is part of his compensation and does not represent an open-market transaction.
Pacific Biosciences (PACB) shareholders approve 16M-share equity plan increase and 2026 auditor
Pacific Biosciences (PACB) shareholders approved an amendment to the 2020 Equity Incentive Plan, reserving an additional 16,000,000 shares for future equity awards. During the June 3, 2026 annual meeting, shareholders also elected Class III directors, ratified Ernst & Young LLP as the independent auditor for 2026, and approved named executive officer compensation on an advisory basis. The meeting saw approximately 65% of outstanding shares represented.
Director William W. Ericson granted 223,492 PACB options at $1.58 exercise price
William W. Ericson, a director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB), was granted 223,492 stock options with an exercise price of $1.58 per share. These options will vest monthly over one year or earlier upon the next annual stockholder meeting, provided he remains a director. The options are set to expire on June 3, 2036.
Christopher Gibson (NASDAQ: PACB) receives 74,497 stock options grant
Christopher Gibson, a director at PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (NASDAQ: PACB), has received a grant of 74,497 stock options. These options have an exercise price of $1.58 per share and are set to expire on June 3, 2036. The options will vest monthly over a one-year period, contingent on his continued service as a director.
PACIFIC BIOSCIENCES (PACB) director granted 223,492 stock options at $1.58
PACIFIC BIOSCIENCES OF CALIFORNIA (PACB) director Christopher M. Smith was granted 223,492 stock options with an exercise price of $1.58 per share, expiring on June 3, 2036. The options will vest monthly over one year, contingent on his continued service as a director. This transaction is classified as a grant or award acquisition, not an open-market purchase, and increases his direct holdings of derivative securities to 223,492 shares.
Pacific Biosciences of California, Inc. 8-K Filing: 2020 Equity Incentive Plan Amendment, Stockholder Voting Results & Company Information (June 2026)
Pacific Biosciences of California, Inc. (NASDAQ: PACB) shareholders approved a significant amendment to the company’s 2020 Equity Incentive Plan, adding 16,000,000 shares for issuance. This amendment, along with the election of directors, ratification of auditors, and executive compensation, was approved at the virtual annual meeting on June 3, 2026. The move aims to support growth, talent retention, and align management interests with shareholders, though it also presents potential for dilution.
Pacific Biosciences reserves 16,000,000 additional shares under 2020 Equity Incentive Plan
Pacific Biosciences' Board of Directors has approved an amendment to its 2020 Equity Incentive Plan, reserving an additional 16,000,000 shares for issuance. This move, subject to stockholder approval on June 3, 2026, aims to expand the company's equity incentive pool. The amendment was recommended by the compensation committee and details are available in an SEC filing from April 23, 2026.
Director John Milligan receives 223,492 options at PacBio (PACB)
John F. Milligan, a director at Pacific Biosciences of California, Inc. (PACB), was granted 223,492 stock options. These options have an exercise price of $1.58 per share, will vest monthly over one year or earlier at the next annual stockholder meeting, and are set to expire on June 3, 2036. This transaction was reported on a Form 4 and is considered a compensation-related award rather than an open-market trade.
Director at Pacific Biosciences (PACB) receives 223,492 stock options grant
Hannah Valantine, a director at Pacific Biosciences (PACB), was granted 223,492 stock options with an exercise price of $1.58 per share, expiring on June 3, 2036. These options will vest monthly over one year or earlier upon the company's next annual meeting, provided she continues her directorship. Following this grant, Valantine directly holds 223,492 derivative securities, reflecting typical compensation rather than open-market trading.
PacBio (PACB) director Kathy Ordonez receives 223,492 stock options at $1.58
PacBio director Kathy Ordonez was granted 223,492 stock options with an exercise price of $1.58 per share, expiring on June 3, 2036. These options were granted at no cost and vest monthly over one year, or earlier upon the next annual stockholder meeting, provided she continues her director service. This transaction is documented in a Form 4 SEC filing, indicating equity compensation rather than a market purchase or sale.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PacBio (PACB) is highlighted as a compelling investment due to its leadership in sequencing technologies, robust product portfolio, and strong first-quarter results. The company's innovative HiFi long-read sequencing and upcoming SPRQ-Nx chemistry are driving growth, despite persistent funding headwinds affecting instrument demand, particularly in academic research. Analysts anticipate positive estimate revisions for 2026, positioning PacBio for future growth.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
PacBio (PACB) is positioned for growth due to its innovative sequencing technologies, strong product portfolio, and positive Q1 2026 results. The company's HiFi long-read and Onso short-read sequencing platforms are expanding its market leadership, despite facing headwinds from funding uncertainties affecting instrument demand. Analysts expect 22.6% growth for 2026 and have narrowed the estimated loss per share, making it a Zacks Rank #2 (Buy) stock.
Barclays downgrades Pacific Biosciences stock rating on catalysts
Barclays has downgraded Pacific Biosciences of California (NASDAQ:PACB) from Equalweight to Underweight, setting a price target of $1.50 due to concerns about the company's cash burn and lack of clear short-term upside catalysts for its SPRQ NX technology. Despite recent positive financial results for Q4 2025 and a new board appointment, the firm believes the stock will underperform due to illiquidity and a heavily weighted catalyst path in the second half of the year. InvestingPro tips also highlight the company's significant debt burden and rapid cash usage.
Pacific Biosciences (PACB) AGM 2024 Summary
This article summarizes the Pacific Biosciences (PACB) 2024 Annual General Meeting (AGM) held on February 3, 2026. Key attendees included the CEO, board members, and executives, with six proposals presented to shareholders. The proposals included the election of Class II directors, ratification of the auditor, an advisory vote on executive compensation, an amendment to the 2020 Equity Incentive Plan, board declassification, and limitation of officer liability.
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
PacBio has commercially launched its SPRQ-Nx sequencing chemistry and new multi-use SMRT Cells for the Revio HiFi sequencing platform, aiming to reduce human genome sequencing costs to under $300 at scale. This development enhances throughput, efficiency, and expands HiFi sequencing capabilities with AI and epigenetic advancements. The company's stock, PACB, has seen an 18.2% gain since the May 26th announcement, reinforcing its competitive position in the growing genomics market.
PacBio (PACB) Launches New Sequencing Technology for Global Dist
Pacific Biosciences of California Inc (PACB) announced the global availability of its new SPRQ-Nx sequencing chemistry and SMRT Cells for the Revio HiFi sequencing platform. This technology aims to reduce the cost of sequencing HiFi genomes, potentially below $300, and enhances methylation detection and DeepConsensus capabilities. Despite this innovation, the company faces financial challenges, as reflected in its moderate GF Score™ of 56 and recent insider selling activity.
AI-tuned PacBio upgrade brings sub-$300 human genomes at scale
PacBio has started shipping its SPRQ-Nx chemistry and multi-use SMRT Cells for the Revio HiFi platform globally, aiming to reduce sequencing costs to below $300 per human genome at scale and by about 30% compared to previous chemistry. This upgrade includes AI-driven DeepConsensus and updated methylation models to enhance accuracy, yield, and epigenetic insights. Beta testing has shown improved performance and lower failure rates, making HiFi sequencing more scalable for large-scale genomic projects.
PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
PacBio has announced the global shipment of its SPRQ-Nx sequencing chemistry and multi-use SMRT Cells for the Revio HiFi sequencing platform. This innovation enables sub-$300 HiFi genomes for large-scale projects, reducing sequencing costs by 30% compared to previous chemistry. Additionally, it features AI-powered DeepConsensus improvements and expanded methylation calling for increased accuracy, yield, and epigenetic insights.
PacBio executives set for fireside chat at Jefferies health conference
PacBio (NASDAQ: PACB) announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2026, at 2:00 PM ET in New York. A live webcast and 30-day replay of the event will be available on the company's investor website. This participation aims to offer additional investor visibility, with past financial results showing improved gross profit and narrowed net loss.
PacBio to Participate in the Jefferies Global Healthcare Conference
PacBio announced its management will participate in a fireside chat at the Jefferies' Global Healthcare Conference on June 4, 2026, in New York. A live webcast and replay of the event will be available on the company's investors page. PacBio is a life science technology company specializing in advanced sequencing solutions.
